Otsuka's VOYXACT Shows Dual Efficacy in IgA Nephropathy

PRINCETON, NJ – March 25, 2026 – Otsuka Pharmaceutical has unveiled compelling new data for its IgA nephropathy (IgAN) treatment, VOYXACT® (sibeprenlimab-szsi), suggesting the drug has a more profound impact on the underlying disease than previously shown. The findings, presented at the 2026 ISN World Congress of Nephrology, demonstrate that VOYXACT not only reduces proteinuria—a key marker of kidney damage—but also significantly clears microscopic hematuria, or blood in the urine, offering a two-pronged benefit for patients with this progressive kidney disease.

These latest analyses from the global Phase 3 VISIONARY trial reinforce the potential of VOYXACT, which targets a central driver of IgAN. For many living with the chronic condition, which often strikes in the prime of adulthood, the news signals a potential shift from managing symptoms to directly confronting the disease's root cause.

A Deeper Impact on Disease Activity

The new data focuses on VOYXACT's effect on microscopic hematuria, an indicator of active glomerular inflammation and injury in the kidneys. According to the interim analysis, patients treated with VOYXACT showed faster and more substantial improvement compared to those on placebo. Among patients who had hematuria at the start of the trial, a striking 82.5% of those receiving sibeprenlimab were free of microscopic hematuria by week 48, compared to just 52.6% in the placebo group.

Furthermore, the speed of this improvement was notable. The median time for patients on VOYXACT to achieve this milestone was only nine weeks, a stark contrast to the 24 weeks it took for the placebo group. This rapid reduction in a key sign of inflammation complements the drug's already established power in reducing proteinuria.

In a previously announced interim analysis from 2025, sibeprenlimab had already met its primary endpoint by demonstrating a -51.2% placebo-adjusted reduction in urine protein at nine months. Proteinuria, or excess protein in the urine, is a primary surrogate marker for kidney disease progression, and its reduction is critical to preserving long-term kidney function.

“The new VISIONARY analyses highlight the differentiated clinical profile of sibeprenlimab and the potential clinical impact of targeting a key immune driver of the disease,” said John Kraus, M.D., Ph.D., executive vice president and chief medical officer at Otsuka. “In addition to meaningful reductions in proteinuria, the observed improvements in hematuria provide complementary evidence of an effect on underlying disease activity. Together, these findings reinforce the potential of VOYXACT to meaningfully improve clinical outcomes for adult IgAN patients at risk for disease progression.”

Targeting the Root Cause of IgAN

IgA nephropathy, also known as Berger's disease, is a complex autoimmune condition where the immune system mistakenly produces a defective form of an antibody called Immunoglobulin A (specifically, galactose-deficient IgA1 or Gd-IgA1). These antibodies clump together, forming immune complexes that get trapped in the kidneys' tiny filters, the glomeruli. This triggers inflammation and scarring, leading to a gradual loss of kidney function that can eventually progress to end-stage renal disease, requiring dialysis or a kidney transplant.

VOYXACT works by targeting and blocking a key signaling protein called A PRoliferation Inducing Ligand, or APRIL. This protein plays a crucial role in promoting the survival of plasma cells that produce the pathogenic Gd-IgA1. By inhibiting APRIL, VOYXACT is designed to strike at the disease's origin, reducing the production of the harmful antibodies that initiate the entire cascade of kidney damage.

This mechanism represents a significant evolution in IgAN treatment. For decades, the standard of care focused on supportive measures like blood pressure control with RAAS blockers and, for higher-risk patients, broad immunosuppression with corticosteroids, which carry a heavy burden of side effects. The development of targeted therapies like VOYXACT marks a paradigm shift towards a more precise, disease-modifying approach.

Navigating a New Treatment Era

VOYXACT's entry into the market comes at a time of unprecedented innovation in IgAN therapy. It received accelerated approval from the FDA based on its ability to reduce proteinuria, a pathway designed to get promising drugs for serious conditions to patients faster. This approval, however, is contingent upon the results of a confirmatory trial verifying its long-term clinical benefit.

The ongoing VISIONARY trial is designed to do just that, evaluating whether the observed reductions in proteinuria and hematuria translate into a tangible slowing of kidney function decline, measured by estimated glomerular filtration rate (eGFR) over 24 months.

Otsuka's drug joins a dynamic and increasingly competitive field. Other recently approved therapies include Tarpeyo (Nefecon), a targeted-release steroid that acts in the gut to reduce IgA production; Filspari (sparsentan), a dual-action receptor blocker; and Iptacopan, which targets the complement system, another part of the immune response implicated in IgAN. Each of these agents tackles the disease from a different angle, reflecting the complexity of its pathogenesis.

This expanding therapeutic arsenal is a boon for patients but presents a new challenge for clinicians. “We are in a rapidly advancing, disease-modifying treatment era,” noted one nephrology expert not involved with the study. “The challenge now is not a lack of options, but determining the optimal sequence and potential combinations of these powerful new agents for each individual patient. We are moving toward personalized medicine, but we need more data and head-to-head trials to build an evidence-based framework.”

What This Means for Patients

For the thousands of individuals living with the uncertainty of IgAN, the latest news on VOYXACT offers a potent dose of hope. The dual efficacy in reducing both proteinuria and hematuria provides stronger evidence that the drug is actively quelling the inflammation that drives kidney destruction. This could mean a future where more patients can slow or even halt the progression of their disease, potentially avoiding the life-altering realities of dialysis and transplantation.

The self-administered, once-monthly subcutaneous injection also offers a convenient and less burdensome alternative to older immunosuppressive regimens. While VOYXACT is an immunosuppressant and carries a risk of increased infections, its clinical trial safety profile was comparable to placebo, with most adverse events reported as mild to moderate.

As the medical community awaits the final results from the VISIONARY trial to confirm long-term kidney preservation, the latest findings provide a powerful indication that the tide is turning. By addressing the fundamental biology of IgA nephropathy, therapies like VOYXACT are not just managing a chronic illness; they are fundamentally rewriting its course.